These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 21560109

  • 1. [Diseases caused by human papilloma viruses].
    Zollner U, Schwarz TF.
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [Abstract] [Full Text] [Related]

  • 2. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 3. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S, Gasparini R, Panatto D, Demarteau N.
    Gynecol Oncol; 2011 Jun 01; 121(3):514-21. PubMed ID: 21334734
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
    Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI.
    Clin Vaccine Immunol; 2012 Feb 01; 19(2):261-7. PubMed ID: 22155768
    [Abstract] [Full Text] [Related]

  • 5. Currently approved prophylactic HPV vaccines.
    Harper DM.
    Expert Rev Vaccines; 2009 Dec 01; 8(12):1663-79. PubMed ID: 19943762
    [Abstract] [Full Text] [Related]

  • 6. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT, Castellsagué X, Garland SM.
    Vaccine; 2012 Nov 20; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [Abstract] [Full Text] [Related]

  • 7. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
    Six L, Joura EA.
    Wien Med Wochenschr; 2007 Nov 20; 157(5-6):130-2. PubMed ID: 17427010
    [No Abstract] [Full Text] [Related]

  • 8. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories, Public Health Services.
    J Infect; 2017 Apr 20; 74(4):393-400. PubMed ID: 28126492
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
    Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, Radley D, Vuocolo S, Haupt RM, Saah A.
    PLoS One; 2013 Apr 20; 8(12):e83431. PubMed ID: 24391768
    [Abstract] [Full Text] [Related]

  • 10. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 20; 13(1):89-99. PubMed ID: 22075171
    [Abstract] [Full Text] [Related]

  • 11. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 12. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.
    Cancer Prev Res (Phila); 2009 Oct 20; 2(10):868-78. PubMed ID: 19789295
    [Abstract] [Full Text] [Related]

  • 13. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL, Joura EA.
    Drugs; 2010 Dec 24; 70(18):2449-74. PubMed ID: 21142263
    [Abstract] [Full Text] [Related]

  • 14. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 15. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K, Romanowski B.
    Drugs; 2011 Mar 05; 71(4):465-88. PubMed ID: 21395359
    [Abstract] [Full Text] [Related]

  • 16. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K, Romanowski B.
    BioDrugs; 2011 Aug 01; 25(4):265-9. PubMed ID: 21815703
    [Abstract] [Full Text] [Related]

  • 17. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun 01; 17(95):103-4. PubMed ID: 18623911
    [Abstract] [Full Text] [Related]

  • 18. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.
    J Natl Cancer Inst; 2012 Nov 21; 104(22):1712-23. PubMed ID: 23104323
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 Nov 21; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 20. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.